Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Salmon protein supplement shows promise for blood and body health

NCT ID NCT07616752

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a salmon protein supplement called ProGo in 14 healthy overweight adults. Participants took either ProGo or whey protein daily for 8 weeks. Researchers measured changes in blood health, body fat, and self-reported hair, skin, and nail quality. The goal was to see if ProGo could improve these markers compared to standard whey protein.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ProGo (salmon protein hydrolysate)
What this could lead to
If it works, this could point toward a natural supplement to support healthy blood and metabolism in overweight adults.
What could go wrong
This is a very small, early study with only 14 people, so results may not apply to everyone. It's also completed, but no major breakthroughs are expected from a dietary supplement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

14 people

The number who actually took part.

Started

Jul 2019

Finished

Jan 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects that have provided written and dated informed consent. * Subjects that are in good health as determined by self-declared medical history and physical examination. * Subjects that are male or female between the ages of 25 and 65 (inclusive). * Subjects that have a Body Mass Index of 25-35. * Subjects that are willing and able to comply with the supplement protocol. * Subject who is willing and able to comply with the supplement intake regimen, lab visits schedule and weekly telephone follow up calls . Exclusion Criteria: * Subjects that currently hyper exercise defined as 3 hours or more for more than five times per week. * Subjects that have used weight loss medications within the past one month of the Screening visit. * Subjects that self-declare a known previous diagnosis of alcohol or substance abuse or have electrolyte abnormalities, thyroid, diabetes, hypogonadism, hepato-renal, musculoskeletal, autoimmune, neurologic, psychiatric disorders, or cancer which are under active drug treatment. * Subjects who self-declare to having a peptic ulcer or active IBS under daily prescription drug treatment. * Subjects who are self-declared to be pregnant, trying to become pregnant, or who are nursing or who are less than 6 months postpartum at enrollment. * Subject that has been hospitalized within the past one-year for any mental or emotional illness. * Subjects who have an active infection or sign/symptoms of an infection. * Subjects who have a known allergy to any of the ingredients in any of the test products. * Subjects that have a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight (bmi > 25) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Spectrum Clinical Research

    Mumbai, Maharashtra, 400020, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.